Tag: biosimilars

Biosimilars aren't exact copies of biologics - tiny manufacturing differences can trigger immune responses. Learn why some patients develop anti-drug antibodies and how regulators ensure safety despite these variations.

Patent expiry means cheaper generics-but only if you plan ahead. Learn what patients and healthcare systems must do now to avoid cost traps, side effects, and supply shortages as hundreds of drugs lose exclusivity.